Bronchopulmonary Dysplasia Treatment Market is expected to garner a value of US$ 661.7 Million by 2032 at a CAGR of 6.1%

The global Bronchopulmonary Dysplasia Treatment Market is expected to be worth US$ 346 million in 2022 and US$ 661.7 million by 2032, growing at a CAGR of 6.1% during the forecast period. The increasing cases of bronchopulmonary dysplasia, as well as the rise in premature births, can be attributed to the growth of the bronchopulmonary dysplasia treatment market. In the historical period 2016-2021, the market for bronchopulmonary dysplasia treatment grew at a CAGR of 5.9%.

Bronchopulmonary Dysplasia Treatment Market: Overview

Companies are focusing on the development of novel treatment option for bronchopulmonary dysplasia for the faster action and quick relief than the conventional dosage forms. For instance, Airway Therapeutics, LLC developed AT-100, a recombinant form of human surfactant protein, for maintaining healthy lung function in infants with bronchopulmonary dysplasia. On the other hand, research are developing stem cell therapy for novel therapeutic modality for attenuating BPD severity. Moreover, the first phase I clinical trial of stem cell transplantation for bronchopulmonary dysplasia is successfully conducted by proving its safety and feasibility in the preterm infants.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-4389

Bronchopulmonary Dysplasia Treatment Market: Drivers and Restraints

According to the Airway estimates, in Europe and the U.S. up to 160,000 infants are at highest risk for the development of BPD collectively, each year. Similarly, With 73.6 million live births in Asia and a preterm rate <32 weeks of approximately 2.2%. Government initiatives, favorable reimbursement policies, increasing prevalence of bronchopulmonary dysplasia, and raise in cases of premature births leading to bronchopulmonary dysplasia are boosting the growth of bronchopulmonary dysplasia treatment market over the forecast period. Growing research and development activities by pharmaceutical companies to develop innovative treatment option for bronchopulmonary dysplasia would boost the market in near future.

Bronchopulmonary dysplasia is a chronic respiratory disease, which is most commonly occurs in premature infants and who received supplemental oxygen or mechanical ventilation. It is also called as respiratory distress syndrome. In addition, bronchopulmonary dysplasia can also occur in infants who experience abnormal lung development or had pre-birth antenatal infection. Most of the infants recover from bronchopulmonary dysplasia, however, some of those have continued lung function and structure abnormalities during adolescence and adulthood. This condition can cause serious complications during infancy and might requires hospitalization and intensive medical care, during the first 2 years after birth. The signs and symptoms for BPS includes shallow, rapid breathing, chronic cough, shortness of breath, flaring of nostrils while breathing, and discoloration of skin owing to low blood oxygen levels. Many cases of BPD are associated with excess oxygen levels and mechanical ventilation. The disease can cause from other conditions such as antenatal infection, maternal complications, preeclampsia, and inflammation of the fetal membranes, that affects the development of the lungs.

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-4389

Bronchopulmonary Dysplasia Treatment Market: Key Players

Some of the players in global bronchopulmonary dysplasia treatment market include Airway Therapeutics LLC, Chiesi Farmaceutici SpA, Insmed Incorporated, MediPost Co., Ltd., Meridigen Biotech Co., Ltd, Syntrix Biosystems, Inc., Therabron Therapeutics, In,

The report covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Value Chain

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico, Brazil)
• Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
• Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
• Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Bronchopulmonary Dysplasia Treatment Market: Segmentation

The global bronchopulmonary dysplasia treatment market is classified on the basis of drug class, therapy type end user, and geography.

For more Report Customization, connect with us at@ https://www.futuremarketinsights.com/customization-available/rep-gb-4389

Based on drug type, the global bronchopulmonary dysplasia treatment market is segmented into the following:

• Bronchodilators
• Diuretics
• Antibiotics
• Steroids
• Immunomodulators
• Surfactant Homeostasis

Based on therapy type, the global bronchopulmonary dysplasia treatment market is segmented into the following:

• Nitric Oxide Therapy
• Protein replacement therapy
• Stem Cell Therapy
• Supplemental Oxygen

Based on end user, the global bronchopulmonary dysplasia treatment market is segmented into the following:

• Hospitals
• Nursing Homes
• Critical Care Centers

Use promo code >> FMITODAY to get flat 20% discount

Report Highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs